Domain Therapeutics

Domain Therapeutics NA is the Canadian subsidiary of Domain Therapeutics, a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets.
Domain Therapeutics discovers GPCR drugs by exploiting its innovative and differentiated technologies. The company’s pipeline is composed of new chemical entities, ranging from hits to preclinical candidates for significant CNS and metabolic disorders.
Establishing a presence in Montreal is part of the company’s strategy for bringing to market a new GPCR-specific biosensor technology, BioSens-All(TM), developed at the Institute of Research in Immunology and Cancer (IRIC) of the University of Montreal in the team of Professor Michel Bouvier. BioSens-All(TM) technology enables a deeper understanding of the GPCR signaling pathways that are activated by each candidate molecule and thus predict its pharmacological profile. For more information visit: www.domaintherapeutics.com.